Prime Medicine (PRME) Q1 2024 Earnings
PRME·Reported May 10, 2024·Before market open
Prime Medicine reported Q1 2024 revenue of $591.0K, missed analyst consensus of $1.9M by $1.3M. Diluted EPS came in at $-0.44, beat the $-0.45 consensus by $0.01.
Revenue
$591.0Kmissed by $1.3M
Consensus: $1.9MDiluted EPS
$-0.44beat by $0.01
Consensus: $-0.45
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Prime Medicine's Q1 2024 earnings report.
Prime Medicine (PRME) reported Q1 2024 earnings on May 10, 2024 before market open.
Prime Medicine reported revenue of $591.0K and diluted EPS of $-0.44 for Q1 2024.
Revenue missed the consensus estimate of $1.9M by $1.3M. EPS beat the consensus estimate of $-0.45 by $0.01.
You can read the 10-Q periodic report (0001628280-24-022473) directly on SEC EDGAR. The filing index links above go to sec.gov.